No Data
No Data
Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript
Buy Rating for Lucid Diagnostics: Solid Test Volumes and Strategic Growth Initiatives Propel Market Position
Buy Rating Affirmed for Lucid Diagnostics Amid Strong Financials and Strategic Growth Initiatives
Lucid Diagnostics Is Maintained at Overweight by Cantor Fitzgerald
Lucid Diagnostics Is Maintained at Overweight by Cantor Fitzgerald
Express News | Cantor Fitzgerald Maintains Overweight on Lucid Diagnostics, Lowers Price Target to $3
No Data